Publication: 4575

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial
      QxMD      Google Scholar   
Citation:
Nat Med vol 32 (2) 717-24
Year:
2026
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Preliminary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
15
Parents:
4265   4410  
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
AstraZeneca, Eli Lilly, GSK  
Grants:
U10CA180821, U10CA180882; UG1CA189960, UG1CA189824, UG1CA232760, UG1CA233180, UG1CA233184, UG1CA233290, UG1CA233329; U10CA180868, UG1CA189867 (NRG Oncology)  
Corr. Author:
 
Authors:
                                                                 
Networks:
CA249, COLUMBIA, CRCWM, IA018, IL043, LAPS-CT018, LAPS-IL036, LAPS-MA036, LAPS-MN026, LAPS-NY016, LAPS-PA015, LAPS-TX011, NC002, NEWMEXICO, NY018, VA002, VT004   
Study
Alliance-A071401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: